Treatment with canagliflozin, an SGLT2 inhibitor, not only helps patients with type 2 diabetes achieve better glycemic control, but significantly reduces the risks of both cardiovascular disease and kidney disease as well, according to results from the CANVAS Program, presented at the 77th Scientific Sessions of the American Diabetes Association. These findings were published simultaneously in the New England Journal of Medicine.
“Coronary heart disease is the biggest killer by far for people with type 2 diabetes. Our findings suggest that not only does canagliflozin significantly reduce the risk of heart disease, it also has many other benefits, too. We found it also reduced blood pressure and led to weight loss. Type 2 diabetes is growing rapidly all over the world, and we need drugs that not only deal with glucose levels, but also protect the many millions of people from the very real risks of stroke and heart attack,” said author Professor Bruce Neal, of The George Institute for Global Health, Newtown, Australia.
Professor Neal presented results from the CANVAS Program, a study of over 10,000 patients in 30 countries. He and fellow researchers found that canagliflozin reduced the overall risk of cardiovascular disease by 14%, reduced the risk of hospitalization for heart failure by 33%, and reduced the risk of serious kidney decline by 40%.
“Both patients and physicians should be tremendously reassured by the results. What we have done is show that the earlier results were not just a one-off. This really is a game changer in the treatment of type 2 diabetes. It not only reduces the risk of heart disease, it also provides real protection against kidney decline, which affects many people with diabetes,” said co-author Professor Vlado Perkovic, executive director, The George Institute.